Portugal
Lymphact is a biopharmaceutical startup founded in 2013 in Portugal with a primary focus on personalized treatments targeting cancer and chronic viral diseases. The company's pioneering product is designed to effectively target cancer and virus-infected cells, including chemotherapy-resistant cancer stem cells and viral reservoirs, all of which are implicated in disease recurrence. Notably, the treatment boasts improved anti-tumor functionality with a notable absence of severe associated side-effects, setting it apart within the industry.
Having received Seed Round investment in January 2014 from Bynd Venture Capital, Lymphact has laid the foundation for its research and development endeavors. Within the biopharma, biotechnology, and pharmaceutical sectors, Lymphact represents an innovative player, with the potential to deliver impactful solutions in the field of personalized medicine and targeted therapeutics.
